Cidel Asset Management Inc. Sells 184,792 Shares of Abbott Laboratories $ABT

Key Points

• Cidel Asset Management cut its Abbott Laboratories stake by 44.8% in the second quarter, selling 184,792 shares and retaining 227,603 shares valued at approximately $20.7 million. Institutional investors collectively own 75.18% of Abbott’s stock.
• Abbott reported quarterly revenue of $12.59 billion, up 13% year over year, and adjusted EPS of $1.31, beating analysts’ $1.28 estimate. The company issued third-quarter EPS guidance of $1.38–$1.46 and full-year guidance of $5.45–$5.60.
• Analysts remain broadly positive, with a consensus “Moderate Buy” rating and an average price target of $118.67; however, Abbott’s valuation above 36 times earnings and 2.3% dividend yield may limit further upside without continued earnings growth.

Cidel Asset Management Inc. trimmed its position in Abbott Laboratories (NYSE:ABT - Free Report) by 44.8% during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 227,603 shares of the healthcare product maker's stock after selling 184,792 shares during the quarter. Cidel Asset Management Inc.'s holdings in Abbott Laboratories were worth $20,653,000 at the end of the most recent reporting period.

A number of other hedge funds also recently made changes to their positions in the company. MidAtlantic Capital Management Inc. purchased a new position in Abbott Laboratories during the 4th quarter valued at approximately $25,000. Cornerstone Financial Management LLC purchased a new stake in shares of Abbott Laboratories during the 4th quarter worth approximately $25,000. Purpose Unlimited Inc. bought a new position in shares of Abbott Laboratories during the 4th quarter valued at approximately $25,000. Portfolio Resources Advisor Group Inc. purchased a new position in shares of Abbott Laboratories in the fourth quarter valued at $26,000. Finally, Abound Financial LLC purchased a new position in shares of Abbott Laboratories in the fourth quarter valued at $26,000. 75.18% of the stock is currently owned by hedge funds and other institutional investors.

Abbott Laboratories Trading Up 0.0%

ABT stock opened at $111.27 on Monday. Abbott Laboratories has a twelve month low of $81.97 and a twelve month high of $137.49. The stock has a market capitalization of $192.53 billion, a price-to-earnings ratio of 36.01, a price-to-earnings-growth ratio of 2.15 and a beta of 0.59. The company has a quick ratio of 0.97, a current ratio of 1.38 and a debt-to-equity ratio of 0.57. The firm's fifty day simple moving average is $97.67 and its two-hundred day simple moving average is $99.77.

Abbott Laboratories (NYSE:ABT - Get Free Report) last released its earnings results on Thursday, July 16th. The healthcare product maker reported $1.31 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.28 by $0.03. Abbott Laboratories had a net margin of 11.65% and a return on equity of 17.69%. The firm had revenue of $12.59 billion during the quarter, compared to analyst estimates of $12.52 billion. During the same quarter last year, the business earned $1.26 EPS. The business's revenue was up 13.0% on a year-over-year basis. Abbott Laboratories has set its Q3 2026 guidance at 1.380-1.46 EPS and its FY 2026 guidance at 5.450-5.60 EPS. As a group, analysts anticipate that Abbott Laboratories will post 5.52 earnings per share for the current year.

Abbott Laboratories Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Monday, August 17th. Shareholders of record on Wednesday, July 15th will be paid a $0.63 dividend. The ex-dividend date of this dividend is Wednesday, July 15th. This represents a $2.52 annualized dividend and a yield of 2.3%. Abbott Laboratories's dividend payout ratio (DPR) is presently 81.55%.

Key Headlines Impacting Abbott Laboratories

Here are the key news stories impacting Abbott Laboratories this week:

• Positive Sentiment: Alphabet AI partnership expands Abbott’s growth opportunity: Abbott and Alphabet announced a multiyear collaboration integrating data from Abbott’s over-the-counter Lingo continuous glucose monitor into the Google Health app. Google’s AI Health Coach is expected to use the data to provide personalized recommendations, potentially increasing Lingo adoption and strengthening Abbott’s position in consumer digital health. Can Abbott Laboratories’ Lingo Partnership With Alphabet Unlock a New Era of AI-Powered Health?
• Positive Sentiment: Wolfe Research upgraded ABT to Outperform: The firm raised its rating from “Peer Perform” and set a $130 price target, implying substantial upside from recent trading levels. The upgrade indicates improving analyst confidence in Abbott’s earnings durability and growth prospects.
• Positive Sentiment: Established Pharmaceuticals remains a growth driver: Abbott’s Established Pharmaceutical Products division is benefiting from emerging-market demand, a broad branded-generics portfolio and biosimilar opportunities. This provides diversification beyond the company’s medical-device businesses. What’s Backing Abbott’s Established Pharmaceuticals Division Growth
• Neutral Sentiment: Recent trading strength reflects broad investor support: Abbott outperformed some medical-product peers during a recent strong market session, while bullish commentary has highlighted the company’s diversified portfolio and long-term growth potential. Abbott Laboratories Stock Outperforms Competitors on Strong Trading Day
• Negative Sentiment: Valuation remains a potential constraint: With a forward-looking earnings multiple above 36 and the stock already well above its recent moving averages, further gains may require continued earnings execution and evidence that newer initiatives such as Lingo can materially contribute to revenue.

Analysts Set New Price Targets

ABT has been the topic of a number of recent research reports. TD Cowen reaffirmed a "buy" rating and set a $115.00 price target on shares of Abbott Laboratories in a research note on Friday, July 17th. Argus dropped their price objective on shares of Abbott Laboratories from $140.00 to $125.00 and set a "buy" rating for the company in a research note on Tuesday, April 21st. Piper Sandler restated an "overweight" rating and issued a $118.00 target price (up from $115.00) on shares of Abbott Laboratories in a report on Friday, July 17th. Wolfe Research upgraded shares of Abbott Laboratories from a "peer perform" rating to an "outperform" rating and set a $130.00 target price on the stock in a research report on Thursday. Finally, Royal Bank Of Canada reiterated an "outperform" rating and issued a $130.00 price target on shares of Abbott Laboratories in a research report on Friday, July 17th. Three research analysts have rated the stock with a Strong Buy rating, twenty have assigned a Buy rating and four have given a Hold rating to the company. According to MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $118.67.

About Abbott Laboratories

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source